Literature DB >> 1855354

Tolerance to nicotinic acid flushing.

R H Stern1, J D Spence, D J Freeman, A Parbtani.   

Abstract

The mechanism of tolerance to nicotinic acid flushing was determined in subjects during a 5-day course of treatment. Objective measures of skin blood flow were used to confirm the development of tolerance. Plasma levels of nicotinic acid showed marked intraindividual variability but were not decreased with the development of tolerance. However plasma levels of 9-alpha 11-beta prostaglandin F2, a stable metabolite of prostaglandin D2, became undetectable in most subjects with the development of tolerance. Thus tolerance is not associated with decreased levels of nicotinic acid or development of tolerance to the prostaglandin mediator, but with decreased levels of the mediator.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1855354     DOI: 10.1038/clpt.1991.104

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  19 in total

1.  GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing.

Authors:  Zoltán Benyó; Andreas Gille; Jukka Kero; Marion Csiky; Marie Catherine Suchánková; Rolf M Nüsing; Alexandra Moers; Klaus Pfeffer; Stefan Offermanns
Journal:  J Clin Invest       Date:  2005-12       Impact factor: 14.808

2.  Familial combined hyperlipoproteinemia.

Authors:  J D Spence
Journal:  CMAJ       Date:  1992-02-15       Impact factor: 8.262

Review 3.  A "hot" topic in dyslipidemia management--"how to beat a flush": optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention.

Authors:  Terry A Jacobson
Journal:  Mayo Clin Proc       Date:  2010-04       Impact factor: 7.616

Review 4.  Niacin: another look at an underutilized lipid-lowering medication.

Authors:  Julia C Creider; Robert A Hegele; Tisha R Joy
Journal:  Nat Rev Endocrinol       Date:  2012-02-21       Impact factor: 43.330

5.  High dietary niacin may increase prostaglandin formation but does not increase tumor formation in ApcMin/+ mice.

Authors:  Alan M Kwong; Brigette L Tippin; Alicia M Materi; Virgilio S Buslon; Samuel W French; Henry J Lin
Journal:  Nutr Cancer       Date:  2011-07-20       Impact factor: 2.900

Review 6.  Does nicotinic acid (niacin) lower blood pressure?

Authors:  H E Bays; D J Rader
Journal:  Int J Clin Pract       Date:  2008-11-28       Impact factor: 2.503

7.  A pilot study of the effects of niacin administration on free fatty acid and growth hormone concentrations in children with obesity.

Authors:  O A Galescu; M K Crocker; A M Altschul; S E Marwitz; S M Brady; J A Yanovski
Journal:  Pediatr Obes       Date:  2016-09-21       Impact factor: 4.000

Review 8.  Nicotinic acid: an old drug with a promising future.

Authors:  E T Bodor; S Offermanns
Journal:  Br J Pharmacol       Date:  2007-11-26       Impact factor: 8.739

Review 9.  Niacin, an old drug with a new twist.

Authors:  Wen-Liang Song; Garret A FitzGerald
Journal:  J Lipid Res       Date:  2013-08-15       Impact factor: 5.922

Review 10.  The mechanism and mitigation of niacin-induced flushing.

Authors:  V S Kamanna; S H Ganji; M L Kashyap
Journal:  Int J Clin Pract       Date:  2009-09       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.